Clinical Evaluation of Fenestration Decompression Combined With Secondary Curettage for Ameloblastoma of the Jaw: Retrospective Radiographic Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04987515

Enrollment

233

Registered

2021-08-03

Start date

2010-01-01

Completion date

2021-07-01

Last updated

2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Cavity Area Reduction Efficiency, the Recurrence of the Tumor

Brief summary

Objectives: To investigate the outcomes of fenestration decompression combined with secondary curettage (FDSC) in the surgical treatment of jaw ameloblastoma. Methods: Medical records of patients diagnosed as multicystic ameloblastoma (MA) or unicystic ameloblastoma (UA) by routine pathology were collected from January 2010 to December 2017 in Ninth People's Hospital, Shanghai JiaoTong University Medical College. Patients were divided into two groups based on the management regimen: FDSC group, and local curettage (LC) group. Patients were followed up for 3-8 years, using panoramic radiography to measure the change of the area of the cystic cavity involved in ameloblastoma and the recurrence or malignant transformation of the tumor in both groups. A total of 233 eligible patients were selected for provisional screening, including 145 patients with MA, and 88 patients with UA.

Interventions

PROCEDUREfenestration decompression combined with secondary curettage

First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

-Medical records of patients who were diagnosed with multicystic ameloblastoma (MA) or unicystic ameloblastoma (UA) by routine pathology were collected from January 2010 to December 2017 in Ninth People's Hospital of Shanghai JiaoTong University Medical College.

Exclusion criteria

* followed up less than 3 years * For FDSC group, fenestration decompression failed * recurrent ameloblastoma * received other type of surgery;

Design outcomes

Primary

Measure	Time frame	Description
Cystic cavity area reduction efficiency	3 years after surgery	(good effect case number + moderate effect case number)/total case number

Secondary

Measure	Time frame	Description
Tumor recurrence rate	3 years after surgery	the recurrence case number/total case number

Other

Measure	Time frame	Description
malignant transformation rate	3 years after surgery	malignant transformation case number/total case number

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026